Stoke Therapeutics, Inc.
STOKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Stoke Therapeutics, Inc. focuses on Biotechnology services and products. Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. Valued at $1.62B, STOK is a small-cap name in its sector. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Market Cap
$1.62B
Beta
1.26
P/E (TTM)
—
P/E (Fwd)
-7.10
EPS (TTM)
$-3.38
EPS (Fwd)
$-3.53
ROE
-61.1%
ROA
-35.9%
Cash
$292.8M
Total Debt
$2.7M
Free CF
-$106.2M
52W Change
-22.4%
Annual Financials
Cash vs Debt
Where STOK stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, STOK finished 19.10% below its 150-day moving average ($30.68) and 20.47% below its 200-day moving average ($31.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STOK overbought or oversold?
At the October 20, 2026 close, STOK's RSI(14) was 43.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $292.8M in cash comfortably exceeding the $2.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$106.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -61.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $12.4M (2022) to $184.4M (2025), reflecting a 1387% increase over the period.
With cash comfortably exceeding debt, STOK has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing STOK.